News and Trends 28 Oct 2016 TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer …I/II in multiple myeloma and also in synovial sarcoma, which Adaptimmune is tackling in collaboration with GSK. Adaptimmune’s TCR technology MSD’s Keytruda is an antibody therapy that blocks the checkpoint… October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2023 InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment …and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults. Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody that acts on the immune system and not… April 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 20 Nov 2018 Why Denmark Is a Strong Player in Europe’s Biotech Industry …helix, the antibody invention, the CRISPR technology is European.” She also pointed out that getting a company through the early stages comes at a lower cost in Europe than in… November 20, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Podcast 15 Dec 2023 Vaxxinity making vaccines to change the world …that these things are foreign and thus induce an immune response, induce an antibody response to in fact neutralize some of these. Different targets for different diseases Hu said that… December 15, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 19 Mar 2025 Breast cancer treatments heat up: Five therapies poised to transform patient outcomes …– The American University in Cairo MUC1 Cancer Antibody – The University of North Carolina at Charlotte Novel Small Molecule Inhibits Metastatic Breast Cancer – Puerto Rico Science, Technology &… March 19, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Mar 2024 Fourteen biotech companies with market caps exceeding $100 billion …clinical development programs, and Seagen Inc. for antibody-drug conjugates for cancer, among others. Vertex Pharmaceuticals – $112 billion The American biotech company reported a $9.9 billion revenue in the financial… March 5, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2017 Merck Outsources the Development of its Nanobody for Psoriasis …Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody is… March 30, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Jan 2023 The biggest biotech trends that will shape 2023 …its entire class.” “The fact that Roche’s own beta amyloid-directed antibody gantenerumab failed phase 3 trials adds more confusion and raises more questions than answers about the viability of this… January 12, 2023 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed? Roche has positive clinical data in support of starting a Phase III trial in Alzheimer’s with an antibody initially developed by MorphoSys. However, the field is full of similar approaches… March 15, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence …footprint in China. Both companies said they are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III SAR408701 (tusamitamab ravtansine; anti-CEACAM5 antibody-drug… August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2022 Sanofi and Innate Pharma expand natural killer cell deal Sanofi and Innate Pharma SA have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform…. December 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email